Hyunje Grace Cho, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cho’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A163549 · Current
Licensed to practise in California · since 2019 · expires 2027-07-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$85,111
Medicare paid this office $85,111 for 507 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 209 | $23,568 | $84 |
| Short return visit (20+ min) | 243 | $16,395 | $53 |
| Destruction of precancer skin growth, 1 growth | 203 | $11,206 | $44 |
| Destruction of skin growth, 1-14 growths | 105 | $7,460 | $62 |
| New patient visit (45+ min) | 55 | $6,400 | $116 |
See all 13 services
| Return visit (30+ min) | 209 | $23,568 | $84 |
| Short return visit (20+ min) | 243 | $16,395 | $53 |
| Destruction of precancer skin growth, 1 growth | 203 | $11,206 | $44 |
| Destruction of skin growth, 1-14 growths | 105 | $7,460 | $62 |
| New patient visit (45+ min) | 55 | $6,400 | $116 |
| Long return visit (40+ min) | 23 | $4,639 | $125 |
| New patient visit (30+ min) | 68 | $4,237 | $62 |
| Biopsy of related skin growth, first growth | 140 | $3,490 | $22 |
| Destruction of precancer skin growth, 2-14 growths | 143 | $1,152 | $2 |
| Biopsy of related skin growth, each additional growth | 32 | $969 | $19 |
| Punch biopsy, first skin growth | 22 | $921 | $40 |
| Injection into skin growth, 1-7 growths | 17 | $584 | $22 |
| Short return visit | 18 | $507 | $27 |
Procedures Medicare counted
| Removal of skin lesions | 319 | More than 83% of doctors who do this |
| Skin biopsy | 97 | More than 75% of doctors who do this |
Who their Medicare patients are
507 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 11% · Women 58% · Also on Medicaid 10% · Health risk score 1.15. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 59% · Diabetes 23% · Depression 23% · Chronic kidney disease 22% · Coronary heart disease 18% · Cancer 16% · Atrial fibrillation 14% · Heart failure 13% · COPD 9% · Stroke 9% · Dementia 4%.
The office billed $390,629, Medicare allowed $117,021 and paid $85,111; for 2,076 services of 34 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 507 | 2,076 | 74 | 1.15 | $390,629 | $85,111 |
| 2023 | 396 | 1,304 | 74 | 1.17 | $220,128 | $61,198 |
| 2022 | 89 | 193 | 71 | 0.97 | $31,520 | $9,430 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Return visit (30+ min) | 103 | $12,184 | $82 |
| New patient visit (45+ min) | 90 | $9,427 | $105 |
| New patient visit (30+ min) | 140 | $8,732 | $62 |
| Short return visit (20+ min) | 125 | $8,428 | $54 |
| Destruction of precancer skin growth, 1 growth | 120 | $7,104 | $45 |
| Long return visit (40+ min) | 18 | $3,482 | $129 |
| Destruction of skin growth, 1-14 growths | 42 | $2,832 | $62 |
| Biopsy of related skin growth, first growth | 66 | $1,612 | $22 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 20 | $617 | $28 |
| Destruction of precancer skin growth, 2-14 growths | 90 | $607 | $2 |
| Short return visit | 14 | $433 | $29 |
2022: 6 services
| Return visit (30+ min) | 23 | $2,353 | $87 |
| New patient visit (30+ min) | 26 | $1,752 | $67 |
| Short return visit (20+ min) | 23 | $1,359 | $59 |
| New patient visit (45+ min) | 11 | $1,309 | $119 |
| Destruction of precancer skin growth, 1 growth | 19 | $862 | $45 |
| Destruction of precancer skin growth, 2-14 growths | 11 | $77 | $2 |
Drugs they prescribed that Part D paid
$239,022
Pharmacies billed $239,022 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 648) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
605 generic and 43 brand-name prescriptions · $239,022 in drug cost · 29 antibiotic prescriptions to 21 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 18 | $68,619 | $3,812 |
| Fluorouracil | 43 | $2,678 | $62 |
| Fluocinonide | 36 | $1,821 | $51 |
| Tacrolimus | 22 | $1,809 | $82 |
| Clobetasol Propionate | 28 | $1,175 | $42 |
See all 14 drugs
| Dupixent | 18 | $68,619 | $3,812 |
| Fluorouracil | 43 | $2,678 | $62 |
| Fluocinonide | 36 | $1,821 | $51 |
| Tacrolimus | 22 | $1,809 | $82 |
| Clobetasol Propionate | 28 | $1,175 | $42 |
| Triamcinolone Acetonide | 82 | $994 | $12 |
| Betamethasone Dipropionate | 15 | $682 | $45 |
| Ketoconazole | 41 | $606 | $15 |
| Hydrocortisone | 79 | $391 | $5 |
| Doxycycline Monohydrate | 13 | $323 | $25 |
| Clotrimazole-Betamethasone | 20 | $279 | $14 |
| Mupirocin | 27 | $219 | $8 |
| Minoxidil | 23 | $217 | $9 |
| Ciclopirox | 19 | $203 | $11 |
Year by year
| 2024 | 648 | 249 | 0% (0) | 7% | $239,022 |
| 2023 | 461 | 179 | None | 7% | $216,146 |
| 2022 | 185 | 78 | None | 15% | $98,846 |
| 2021 | 134 | 57 | 0% (0) | 14% | $69,281 |
| 2020 | 175 | 84 | 0% (0) | None | $18,010 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Dupixent | 16 | $58,771 | $3,673 |
| Tacrolimus | 23 | $2,830 | $123 |
| Fluorouracil | 24 | $1,892 | $79 |
| Triamcinolone Acetonide | 52 | $796 | $15 |
| Fluocinonide | 14 | $557 | $40 |
| Ketoconazole | 35 | $512 | $15 |
| Clobetasol Propionate | 15 | $422 | $28 |
| Ciclopirox | 19 | $294 | $15 |
| Hydrocortisone | 47 | $294 | $6 |
| Minoxidil | 27 | $270 | $10 |
| Prednisone | 15 | $239 | $16 |
| Valacyclovir | 11 | $216 | $20 |
| Mupirocin | 20 | $211 | $11 |
2022: 3 drugs
| Metronidazole | 11 | $793 | $72 |
| Prednisone | 15 | $219 | $15 |
| Triamcinolone Acetonide | 18 | $178 | $10 |
2021: 3 drugs
| Ketoconazole | 14 | $347 | $25 |
| Triamcinolone Acetonide | 13 | $212 | $16 |
| Prednisone | 13 | $183 | $14 |
2020: 5 drugs
| Valacyclovir | 11 | $347 | $32 |
| Triamcinolone Acetonide | 17 | $295 | $17 |
| Ketoconazole | 15 | $283 | $19 |
| Finasteride | 11 | $209 | $19 |
| Prednisone | 12 | $95 | $8 |
Money from drug and device companies
$46 in 2023
| 2023 | 1 | 3 | None | $46 |
| 2020 | 1 | 1 | None | $20 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Cibinqo | $46 | 3 payments
|
See all 3 published payments
| Pfizer | Education · 2023-05-12 | Cibinqo | $15 |
| Pfizer | Education · 2023-05-03 | Cibinqo | $15 |
| Pfizer | Education · 2023-04-12 | Cibinqo | $15 |
See earlier years (2020)
2020: $20
| AbbVie | Skyrizi | $20 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1689170524
- Licence
- CA A163549California A163549: Current · expires 2027-07-31
- Trained
- Stanford University School of Medicine, 2018
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2018-03-31
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 450 Broadway St # B, Redwood City, CA, 94063
This office lists an electronic records connection.